CurrentUnitedHealthcarePolicy 2025 P 1146-16

UnitedHealthcare Pharmacy Clinical Pharmacy Programs - Harvoni

UnitedHealthcare prior authorization policy for Harvoni (ledipasvir/sofosbuvir) detailing approved HCV genotypes, combination therapy restrictions, authorization duration, and ancillary program rules for members covered under applicable benefit plans.

Policy Summary

PayerUnitedHealthcare

PolicyUnitedHealthcare Pharmacy Clinical Pharmacy Programs - Harvoni

Policy CodePolicy 2025 P 1146-16

Change TypeAnnual updates / reorganized criteria

Effective DateJan 1, 2026

Next Review Date

Key ActionPrior authorization/notification required for Harvoni; approvals issued for 12 months and may be granted based on documentation, prior claim/medication history, diagnosis codes, and/or claim logic.

SourceLink

POLICY UPDATE CHANGES

Reorganized criteria so that chronic HCV infection for treatment-experienced patients and other specific populations are addressed in one section; simplified cirrhosis status criteria and updated authorization to 12 months.

Added cirrhosis criteria for treatment of chronic hepatitis C genotype 4, 5 or 6.

Added criteria for genotype 1 patients with decompensated cirrhosis and for post-liver transplant genotype 1 or 4 patients per updated FDA label.

1,4,5,6Covered genotypes

12 moAuthorization duration

Not allowedCombination therapy

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

Policy number 2025 P 1146-16 (status: CURRENT) covers Harvoni (ledipasvir/sofosbuvir) with criteria. Coverage stance: covered_with_criteria. Scope: UnitedHealthcare prior authorization policy for Harvoni detailing approved HCV genotypes, restrictions on combination therapy, authorization duration, and program rules for applicable benefit plans. Short description: Harvoni is a fixed-dose combination indicated for chronic hepatitis C virus infection for genotypes 1, 4, 5, or 6 in adults and pediatric patients 3 years of age or older, with regimen notes for compensated versus decompensated cirrhosis and for post-liver transplant per the label.

Key Coverage Details

Covered genotypesGenotypes 1, 4, 5, or 6

Additional genotype-specific usesGenotype 1 with decompensated cirrhosis (with ribavirin); post-liver transplant genotype 1 or 4 (with ribavirin)

Authorization duration12 months

Effective date2026-01-01

Last review date2025-10-01

Drug definitionFixed-dose combination of ledipasvir and sofosbuvir for chronic HCV treatment (Harvoni)

Initial Therapy Criteria

Initial Authorization - Harvoni

Harvoni will be approved based on both of the following criteria:

Diagnosis of chronic hepatitis C genotype 1, 4, 5 or 6 infection
Patient is not receiving Harvoni in combination with another HCV direct acting antiviral agent (e.g., Sovaldi (sofosbuvir))

Authorization / Continuation Criteria

Authorization Duration

Authorization terms

Authorization will be issued for 12 months

Program and Coverage Notes / Additional Clinical Rules

State mandates may apply; federal regulatory requirements and member specific benefit plan coverage may impact coverage criteria
UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic
Supply limits may be in place

Provider Actions and Requirements

Prior Authorization

Prior authorization required

Prior authorization/notification is required for Harvoni. Approvals will be issued for 12 months. Approvals may be granted based on documentation and/or prior claim/medication history, diagnosis codes (ICD-10) and/or claim logic.

Documentation Required

Document genotype and combination therapy status

Provider must document a diagnosis of chronic hepatitis C genotype 1, 4, 5, or 6 and that Harvoni will not be used in combination with another HCV direct-acting antiviral agent (for example, sofosbuvir/Sovaldi).

Applicable Codes

HCPCS/NDC/CPT codesmixed

No codes listed

Relevant diagnosis codes mentionedICD-10

Chronic hepatitis C (genotype 1, 4, 5, or 6) - specific ICD-10 codes not listed in policy

Clinical Evidence & References

Evidence: Prescribing information — Harvoni package insert, December 2024.

Evidence: Guideline reference — American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. Recommendations for Testing, Managing, and Treating Hepatitis C (accessed 2025).

Background

Harvoni is a fixed-dose combination of ledipasvir and sofosbuvir indicated for the treatment of chronic hepatitis C virus (HCV) in adults and pediatric patients 3 years of age or older. Indications include infection with HCV genotypes 1, 4, 5, or 6 without cirrhosis or with compensated cirrhosis. For genotype 1 with decompensated cirrhosis, Harvoni is indicated in combination with ribavirin. For liver transplant recipients with genotype 1 or 4 without cirrhosis or with compensated cirrhosis, Harvoni is indicated in combination with ribavirin, per the label.

Definitions:

Harvoni — Fixed-dose combination of ledipasvir and sofosbuvir for chronic HCV treatment.

Revision History

10/2025revisedLatest

2/2024added

Added cirrhosis criteria for treatment of chronic hepatitis C genotype 4, 5 or 6.

12/2016added